Vaccinated patients survived 81 percent longer than those who refused the shot
At a major oncology congress in Berlin, researchers presented evidence that mRNA COVID vaccines — the same Moderna and Pfizer formulations developed for pandemic prevention — appear to meaningfully extend the lives of cancer patients when used alongside existing immunotherapies. Among those with advanced lung cancer, the vaccinated lived nearly twice as long as the unvaccinated, a finding that quietly reframes what this technology may ultimately be for. Science, it seems, sometimes discovers its deepest purposes only after the first door has been opened.
- Cancer patients with advanced non-small cell lung cancer who received mRNA vaccines survived a median of 37 months — versus just 20 months for the unvaccinated — an 81% difference that is difficult to dismiss.
- The vaccines don't replace cancer treatment; they appear to sharpen the immune system's response to existing immunotherapy drugs, amplifying tools doctors already have in hand.
- MD Anderson researchers emphasize that these vaccines are affordable and widely available, offering a potential lifeline to patients whose cancers have resisted every other approach.
- Similar survival benefits were observed in metastatic melanoma patients, suggesting the effect may extend across multiple aggressive cancer types.
- The findings land in a politically charged moment — as U.S. health leadership continues to question vaccine efficacy — injecting new urgency into what is at stake when that skepticism shapes policy.
- Larger trials are still needed, but presentation at a premier European oncology conference signals the medical establishment is taking this seriously, and the implications for oncology protocols could be far-reaching.
A study presented at the 2025 European Society for Medical Oncology Congress in Berlin has uncovered something unexpected in the data on mRNA COVID vaccines: cancer patients who received them lived significantly longer. Among 180 people with advanced non-small cell lung cancer, those vaccinated with Moderna or Pfizer shots survived a median of 37.33 months, compared to 20.6 months for the unvaccinated — roughly 81 percent longer.
The vaccines did not replace conventional treatment. Instead, they appear to enhance how well immunotherapy drugs already work in the body, priming the immune system to respond more powerfully to existing cancer medicines. Dr. Adam Grippin of MD Anderson Cancer Center noted a critical dimension: these vaccines are affordable and widely accessible, meaning the benefit extends even to patients whose cancers have resisted other treatments.
Similar survival advantages were found in patients with metastatic melanoma, suggesting the effect is not limited to a single cancer type. The findings arrive as public debate over vaccine safety continues in the United States, lending particular weight to data that reframes mRNA technology not merely as a pandemic tool, but as a potential pillar of cancer care.
Checkpoint inhibitors and other immunotherapies have transformed oncology over the past decade, yet they remain inconsistent across patients. If mRNA vaccines can reliably improve their performance, it opens a meaningful new path for those who have run out of options. Larger trials will be needed to confirm the effect at scale, but the research has cleared peer scrutiny at one of medicine's most prominent stages — and for patients facing advanced diagnoses, the possibility of more than a year of additional survival is anything but abstract.
A study presented at the 2025 European Society for Medical Oncology Congress in Berlin has found that cancer patients who received mRNA-based COVID vaccines—specifically those made by Moderna or Pfizer/BioNTech—lived significantly longer than their unvaccinated counterparts. Among 180 patients with advanced non-small cell lung cancer, the difference was stark: vaccinated patients had a median survival of 37.33 months, while unvaccinated patients survived a median of 20.6 months. That gap represents roughly 81 percent longer survival for those who received the shots.
The mechanism appears to work through enhancement of existing cancer therapies. The vaccines did not replace conventional treatment but rather amplified how well immunotherapies worked in the body. Dr. Adam Grippin from MD Anderson Cancer Center highlighted a crucial advantage: these vaccines are affordable and widely available, making them accessible even to patients whose cancers had resisted other forms of treatment. For people facing advanced disease with limited options, that combination of efficacy and accessibility carries real weight.
The research also examined patients with metastatic melanoma, another aggressive cancer form, and found similar survival benefits. The findings arrive amid ongoing public debate about vaccine efficacy in the United States, where Health Secretary Robert F. Kennedy Jr. has continued to raise questions about vaccine safety and effectiveness. This new data on cancer survival represents a different application of mRNA technology than its original COVID prevention purpose, suggesting the platform may have broader utility in oncology than previously understood.
What makes these results noteworthy is not just the survival extension but the mechanism: the vaccines appear to work by priming the immune system to work better alongside existing cancer drugs. Immunotherapy drugs like checkpoint inhibitors have transformed cancer treatment over the past decade, but they don't work equally well for all patients. If mRNA vaccines can reliably improve how those drugs perform, it opens a new avenue for patients who have exhausted other options or whose tumors have proven resistant to standard approaches.
The study's scope—180 patients with advanced lung cancer—is substantial enough to suggest the finding is not a statistical anomaly, though larger trials would be needed to confirm the effect across broader populations and cancer types. The presentation at a major European oncology conference indicates the research has passed peer scrutiny and is being taken seriously by the medical establishment. For patients and families facing advanced cancer diagnoses, the possibility that a vaccine already in widespread use might extend survival by more than a year represents a tangible shift in what treatment could mean.
Citas Notables
Dr. Adam Grippin from MD Anderson Cancer Center emphasized the affordability and accessibility of vaccines in improving patient outcomes, even for those with treatment-resistant conditions.— Dr. Adam Grippin, MD Anderson Cancer Center
La Conversación del Hearth Otra perspectiva de la historia
Why would a COVID vaccine help with cancer survival at all? These seem like completely different diseases.
The vaccine doesn't treat the cancer directly. It trains the immune system to recognize threats more effectively. When that primed immune system then encounters cancer drugs designed to unlock immune responses, the combination works better together.
So it's not the vaccine doing the work—it's making the existing cancer drugs more powerful?
Exactly. The cancer drugs were already there, already being used. The vaccine appears to amplify their effect. For patients whose tumors had stopped responding to those drugs alone, that amplification can mean the difference between months and years.
The survival difference is huge—37 months versus 20 months. Is that real, or could it be something else about who got vaccinated?
That's the right skepticism. The study controlled for that as much as possible, but you're right that vaccinated patients might differ in other ways—maybe they were healthier, or more engaged with their care. Larger studies will help clarify. But the magnitude is striking enough that researchers are taking it seriously.
What about the cost? If these are expensive new treatments, accessibility doesn't matter.
That's what makes this potentially transformative. These are existing vaccines, already manufactured at scale, already affordable. You're not inventing a new drug. You're using something that already exists in a new way.